New Meningitis Vaccine

FDA approves Novartis meningitis vaccine for teens, adults.
The AP (2/23) reports, "Novartis AG said Monday that its meningitis vaccine Menveo has been approved for use in teenagers and adults by the US Food and Drug Administration." Menveo "is a vaccine against four common types of bacterial meningitis," and the FDA "approved the drug for people between 11 and 55, Novartis said." Novartis also "said it is continuing clinical trials for the use of the vaccine in other age groups." MedPage Today (2/22, Petrochko) noted that the vaccine covers "disease serogroups -- A, C, Y, and W-135."